

Lewis Base Catalyzed Synthesis of Multisubstituted 4-Sulfonyl-1*H*-Pyrazole Involving a Novel 1,3-Sulfonyl Shift


Yu Zhu, Wen-Ting Lu, Hong-Chao Sun, and Zhuang-Ping Zhan*

Department of Chemistry, College of Chemistry and Chemical Engineering,
Xiamen University, Xiamen 361005, Fujian, P. R. China

zpzhan@xmu.edu.cn

Received June 28, 2013

ABSTRACT



A facile synthesis of highly substituted 4-sulfonyl-1*H*-pyrazoles from *N*-propargylic sulfonylhydrazone derivatives has been developed. Allenic sulfonamide formation and 1,3-sulfonyl shift were established to be the critical steps of this transformation.

Pyrazoles and their derivatives have been recognized as important frameworks in pharmaceutical and agrochemical science,¹ and certain pyrazole derivatives including Celebrex (selective COX-2 inhibition) and Zoniporide (selective human NHE-1 inhibition) have been developed into clinical drugs. Owing to the attractive medicinal properties of pyrazoles, new approaches for the efficient

assembly of different pyrazoles have attracted great interest. Efficient strategies have been developed with the aim of the preparation of diverse substitution pyrazoles.² Conventional approaches for the synthesis of compounds containing pyrazole skeletons involve either the modification of the pre-existing pyrazole precursors through the introduction of new groups³ or synthesis of a new pyrazole ring from creation of C–N and C–C bonds.⁴

Previous studies from our group have reported a concise approach to prepared *N*-propargylic *N*-sulfonylhydrazones through FeCl₃-catalyzed nucleophilic substitution

(1) (a) Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M. *J. Med. Chem.* **1997**, *40*, 1347. (b) Guzman-Perez, A.; Wester, R. T.; Allen, M. C.; Brown, J. A.; Buchholz, A. R.; Cook, E. R.; Day, W. W.; Hamanaka, E. S.; Kennedy, S. P.; Knight, D. R. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 803. (c) Chimenti, F.; Fioravanti, R.; Bolasco, A.; Manna, F.; Chimenti, P.; Secci, D.; Befani, O.; Turini, P.; Ortuso, F.; Alcaro, S. *J. Med. Chem.* **2007**, *50*, 425. (d) Okuno, S.; Saito, A.; Hayashi, T.; Chan, P. H. *J. Neurosci.* **2004**, *24*, 7879. (e) Wasyluk, C.; Zheng, H.; Castell, C.; Debussche, L.; Multon, M.-C.; Wasyluk, B. *Cancer Res.* **2008**, *68*, 1275. (f) Wu, C.-H.; Hung, M.-S.; Song, J.-S.; Yeh, T.-K.; Chou, M.-C.; Chu, C.-M.; Jan, J.-J.; Hsieh, M.-T.; Tseng, S.-L.; Chang, C.-P. *J. Med. Chem.* **2009**, *52*, 4496. (g) Ivachtchenko, A. V.; Golovina, E. S.; Kadieva, M. G.; Kysil, V. M.; Mitkin, O. D.; Tkachenko, S. E.; Okun, I. M. *J. Med. Chem.* **2011**, *54*, 8161. (h) Ivachtchenko, A. V.; Dmitriev, D. E.; Golovina, E. S.; Kadieva, M. G.; Koryakova, A. G.; Kysil, V. M.; Mitkin, O. D.; Okun, I. M.; Tkachenko, S. E.; Vorobiev, A. A. *J. Med. Chem.* **2010**, *53*, 5186. (i) Ivachtchenko, A. V.; Golovina, E. S.; Kadieva, M. G.; Kysil, V. M.; Mitkin, O. D.; Vorobiev, A. A.; Okun, I. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 4273.


(2) For reviews on the synthesis of pyrazole, see: (a) Fustero, S.; Sainchez-Rosello, M.; Barrio, P.; Simoin-Fuentes, A. *Chem. Rev.* **2011**, *111*, 6984. (b) Janin, Y. L. *Chem. Rev.* **2012**, *112*, 3924. (c) Dadiboyena, S.; Nefzi, A. *Eur. J. Med. Chem.* **2011**, *46*, 5258. (d) Svete, J. *ARKIVOC* **2006**, *7*, 35. (e) Anwar, H.; Elnagdi, M. *ARKIVOC* **2009**, *1*, 198. (f) Makino, K.; Kim, H. S.; Kurasawa, Y. *J. Heterocycl. Chem.* **1998**, *35*, 489. (g) Makino, K.; Kim, H. S.; Kurasawa, Y. *J. Heterocycl. Chem.* **1999**, *36*, 321.

(3) For recent examples, see: (a) Ye, M.; Edmunds, A. J.; Morris, J. A.; Sale, D.; Zhang, Y.; Yu, J.-Q. *Chem. Sci.* **2013**, *4*, 2374. (b) Goikhman, R.; Jacques, T. L.; Sames, D. *J. Am. Chem. Soc.* **2009**, *131*, 3042. (c) Grosse, S.; Pillard, C.; Massip, S.; Léger, J. M.; Jarry, C.; Bourg, S.; Bernard, P.; Guillaumet, G. *Chem.—Eur. J.* **2012**, *18*, 14943. (d) Yan, T.; Chen, L.; Bruneau, C.; Dixneuf, P. H.; Doucet, H. *J. Org. Chem.* **2012**, *77*, 7659. (e) Pan, X.; Luo, Y.; Wu, J. *J. Org. Chem.* **2013**, *78*, 5756. (f) Ma, W.; Graczyk, K.; Ackermann, L. *Org. Lett.* **2012**, *14*, 6318. (g) Mateos, C.; Mendiola, J.; Carpintero, M.; Minguez, J. M. *Org. Lett.* **2010**, *12*, 4924. (h) Enders, D.; Grossmann, A.; Gieraths, B.; Düzdemir, M.; Merckens, C. *Org. Lett.* **2012**, *14*, 4254.

(4) For recent examples, see: (a) Neumann, J. J.; Suri, M.; Glorius, F. *Angew. Chem., Int. Ed.* **2010**, *49*, 7790. (b) Kinjo, R.; Donnadieu, B.; Bertrand, G. *Angew. Chem., Int. Ed.* **2011**, *50*, 5560. (c) Hao, L.; Hong, J. J.; Zhu, J.; Zhan, Z. P. *Chem.—Eur. J.* **2013**, *19*, 5715. (d) Wang, L.; Yu, X.; Feng, X.; Bao, M. *J. Org. Chem.* **2013**, *78*, 1693. (e) Attanasi, O. A.; Favi, G.; Geronikaki, A.; Mantellini, F.; Moscatelli, G.; Paparisa, A. *Org. Lett.* **2013**, *15*, 2624. (f) Wang, H.; Zhao, Y. L.; Li, L.; Zhang, Z. W.; Liu, Q. *Adv. Synth. Catal.* **2013**, *355*, 1540. (g) Wang, L.; Huang, J.; Gong, X.; Wang, J. *Chem.—Eur. J.* **2013**, *19*, 7555. (h) Li, X.; He, L.; Chen, H.; Wu, W.; Jiang, H. *J. Org. Chem.* **2013**, *78*, 3636. (i) Dissanayake, A. A.; Odom, A. L. *Chem. Commun.* **2012**, *48*, 440.

of propargylic acetates with *N*-sulfonylhydrazones.⁶ The *N*-propargylic substitution products underwent a copper-(I)-catalyzed [3,3]-rearrangement affording (1*E*,3*E*)-2-sulfonyl-1,3-dienes (Scheme 1).^{6a} As part of ongoing research on *N*-propargylic sulfonylhydrazones, we herein report a Lewis base catalyzed synthesis of 4-sulfonyl-1*H*-pyrazoles in moderate to good yields. Allenic sulfonamide formation and 1,3-sulfonyl shift were established to be critical steps in this transformation.

Scheme 1. Reaction of *N*-Propargylic Sulfonylhydrazones



Recently, base-promoted construction of pyrroles,^{5a} oxazoles,^{5b} and imidazoles^{5c} from propargylic amides or propargylic amines involving sulfonyl group shift have been developed. Different from those transformations, which introduced the sulfonyl group to the exocyclic alkyl group of heterocycles,⁵ here we report a sulfonyl group migration to the 4-position of 1*H*-pyrazole. The recent studies indicate that pyrazole derivatives containing a sulfonyl substituent display a variety of biological activities.^{1g–i}

In our initial study, we decided to investigate the reaction conditions that would improve the yield of **3a** using **1a** as the reactant (Table 1). We treated the **1a** in 1,2-dichloroethane with 5 mol % of DMAP at 80 °C. The desired product **3a** was observed in 40% yield (Table 1, entry 1). The reaction also took place in solvents such as THF (52%), PhMe (47%), CH₃CN (50%), and dioxane (15%) (Table 1, entries 2, 3, 4, and 5). Subsequently, the synthesis of pyrazole was investigated in the mixed solvents of THF and NEt₃ (Table 1, entries 6–8). The best mixture volume ratio for THF and NEt₃ was 5:1, which afforded the product **3a** in 78% yield (Table 1, entry 7). When Lewis bases PPh₃ or DABCO were utilized in the same mix-solvent, the reaction proceeded to afford **3a** in 60% and 10% yields respectively (Table 1, entries 9 and 10). Other bases, such as DBU and Cs₂CO₃, were also screened but failed to promote this transformation (Table 1, entries 11 and 12). However, the reaction occurred to afford **2a** in 81% yield at room temperature for 0.5 h, and no desired product **3a** was detected after the reaction time was

prolonged (Table 1, entry 13). Absence of catalyst led to complete recovery of **1a** (Table 1, entry 14). Thus, the most suitable reaction conditions for the formation of **3a** were established (Table 1, entry 7).

Table 1. Screening for the Reaction Conditions^a

entry	catalyst (5 mol %)	solvent	time (h)	yield ^b (%) of 3a (2a)
1	DMAP	DME	4	40
2	DMAP	THF	4	52
3	DMAP	PhMe	6	47
4	DMAP	CH ₃ CN	3	50
5	DMAP	dioxane	1	15
6	DMAP	V _T :V _N ^c = 3:1	3	76
7	DMAP	V _T :V _N = 5:1	3	78
8	DMAP	V _T :V _N = 100:1	4	56
9	PPh ₃	V _T :V _N = 5:1	4	60
10	DABCO	V _T :V _N = 5:1	4	10
11	DBU	V _T :V _N = 5:1	4	trace
12	Cs ₂ CO ₃	V _T :V _N = 5:1	4	trace
13	DMAP	V _T :V _N = 5:1	0.5	0 (81) ^d
14		V _T :V _N = 5:1	4	n.r. ^e

^a Reaction conditions: **1a** (0.5 mmol), solvent (5 mL), 80 °C. ^b Isolated yield. ^c Mixture volume ratio of THF and NEt₃. ^d The reaction was performed at room temperature. ^e n.r. = no reaction.

To broaden the scope of this reaction, we carried out the reaction of the *N*-propargylic *N*-sulfonylhydrazone derivatives **1** under the optimized conditions (summarized in Table 2). The substrates **1a** (R¹ = 4-MeC₆H₄) and **1b** (R¹ = Ph) gave the desired results, providing **3a** and **3b** in 78% and 64% yields, respectively (Table 2, entries 1 and 2). The electron-donating *N*-sulfonylhydrazone **1c** (R¹ = 4-MeOC₆H₄) was also successfully employed in the reaction to give product **3c** in 61% yield (Table 2, entry 3). The electron-deficient *N*-sulfonylhydrazone **1d** (R¹ = 4-BrC₆H₄) reacted smoothly affording the product **3d** in 83% yield (Table 2, entry 4). The results suggested that reactant **1e** (R¹ = Me) failed to form 4-methylsulfonyl-1*H*-pyrazole (**3e**) (Table 2, entry 5). Gratifyingly, reactants (**1f–k**) bearing a terminal alkyne group (R⁴ = H) successfully afforded the desired products (**3f–k**) in good isolated yields in a short reaction time (Table 2, entries 6–11). The reactant **1l** (R⁴ = TMS) underwent protodesilylation under these base cyclization conditions with the same products **3f** obtained in 47% yield (Table 2, entry 12). No reaction of **1m** (R³ = H) and **1n** (R³ = C₂H₅) occurred under normal conditions (Table 2, entries 13 and 14). Unfortunately, the results suggested that internal alkynes **1o** (R⁴ = *n*-C₄H₉) failed to form the corresponding pyrazole. Other internal alkynes **1p** and **1q** (R⁴ = *t*-C₄H₉ and 1-cyclohexenyl) afforded allenamides **2p** and **2q** as the major products (Table 2, entries 16 and 17).

(5) (a) Xin, X.; Wang, D.; Li, X.; Wan, B. *Angew. Chem., Int. Ed.* **2012**, *51*, 1693. (b) Yu, X.; Xin, X.; Wan, B.; Li, X. *J. Org. Chem.* **2013**, *78*, 4895. (c) Jiang, Z.; Lu, P.; Wang, Y. *Org. Lett.* **2012**, *14*, 6266.


(6) (a) Zhu, Y.; Tang, H. T.; Zhan, Z. P. *Adv. Synth. Catal.* **2013**, *355*, 1291. (b) Zhan, Z.-p.; Yu, J.-l.; Liu, H.-j.; Cui, Y.-y.; Yang, R.-f.; Yang, W.-z.; Li, J.-p. *J. Org. Chem.* **2006**, *71*, 8298.

shift and formation of **7** are shown. In path **I**, Lewis base facilitates the sulfonyl dissociation, and then intermolecular addition occurs to afford intermediate **7**. In path **II**, nucleophilic addition of Lewis base **B** such as DMAP to the terminal sp^2 carbon atom of allene pushes electron density into the sulfonamide moiety to afford transition state **4**, then the N–S bond is broken which allows the 1,3-sulfonyl shift and generates transition state **6**, and then electron transfer affords **7**. α,β -Unsaturated imine **7** undergoes intramolecular Michael addition providing zwitterionic species **8**. Finally, **8** rearranges to pyrolyze **3** via a 1,3-H shift and electron transfer.

In order to establish whether the shift of the sulfonyl group occurred in an intramolecular or intermolecular pathway, we performed a crossover experiment between equimolar amounts of reactants **1f** and **1i** which yields the corresponding products **3f** and **3i** in 82% and 83% yields, respectively, and the crossover products **3g** and **3h** were not detected (Scheme 2, eq 2, determined by HPLC). This result clearly indicated that migration of the sulfonyl group proceeds in an intramolecular manner. Therefore, path **II** might be the possible pathway envisioned for this 1,3-sulfonyl migration.

In summary, a facile approach for the synthesis of highly substituted multisubstituted 4-sulfonyl-1*H*-pyrazole from *N*-propargylic *N*-sulfonylhydrazone derivatives has been developed. A key feature of the reaction is the straightforward

Scheme 3. Proposed Mechanism



introduction of sulfonyl group to the 4-position of 1*H*-pyrazole. Studies aiming at exploring mechanistic aspects of this reaction and developing further transformations of *N*-propargylic *N*-sulfonylhydrazone derivatives are ongoing.

Acknowledgment. Financial support from the National Natural Science Foundation of China (No. 21072159 and 21272190) and PCSIRT at Xiamen University is gratefully acknowledged.

Supporting Information Available. Experimental procedures and characterization of compounds **3a–k,r–z** and **2a,p,q**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

The authors declare no competing financial interest.

(8) For reviews and recent examples of Lewis base catalysis, see: (a) Denmark, S. E.; Beutner, G. L. *Angew. Chem., Int. Ed.* **2008**, *47*, 1560. (b) Heinrich, M. R.; Klisa, H. S.; Mayr, H.; Steglich, W.; Zipse, H. *Angew. Chem., Int. Ed.* **2003**, *42*, 4826. (c) Yoshida, M.; Saito, K.; Fujino, Y.; Doi, T. *Chem. Commun.* **2012**, *48*, 11796. (d) Dadwal, M.; Mobin, S. M.; Namboothiri, I. N. *Org. Biomol. Chem.* **2006**, *4*, 2525. (e) Hills, I. D.; Fu, G. C. *Angew. Chem., Int. Ed.* **2003**, *42*, 3921. (f) Yoshida, M.; Fujino, Y.; Saito, K.; Doi, T. *Tetrahedron* **2011**, *67*, 9993.

(9) For representative examples of sulfonyl shift, see: (a) Bendikov, M.; Duong, H. M.; Bolanos, E.; Wudl, F. *Org. Lett.* **2005**, *7*, 783. (b) Yeom, H. S.; So, E.; Shin, S. *Chem.—Eur. J.* **2011**, *17*, 1764. (c) Nakamura, I.; Yamagishi, U.; Song, D.; Konta, S.; Yamamoto, Y. *Angew. Chem., Int. Ed.* **2007**, *119*, 2284. (d) Nakamura, I.; Yamagishi, U.; Song, D.; Konta, S.; Yamamoto, Y. *Chem.—Asian J.* **2008**, *3*, 285. (e) Prasad, B.; Adepu, R.; Sandra, S.; Rambabu, D.; Krishna, G. R.; Reddy, C. M.; Deora, G. S.; Misra, P.; Pal, M. *Chem. Commun.* **2012**, *48*, 10434. (f) DeKorver, K. A.; Johnson, W. L.; Zhang, Y.; Hsung, R. P.; Dai, H.; Deng, J.; Lohse, A. G.; Zhang, Y.-S. *J. Org. Chem.* **2011**, *76*, 5092. (g) Zhu, Y.; Wen, S.; Yin, G.; Hong, D.; Lu, P.; Wang, Y. *Org. Lett.* **2011**, *13*, 3553. (h) Lee, Y. T.; Chung, Y. K. *J. Org. Chem.* **2008**, *73*, 4698.